

## Data supplement

Table D51 Study characteristics

Study, location	Design, intervention, dose range and mean	Duration of treatment	Diagnostic criteria, minimum severity and duration of illness	Number of participants n (% female)	Total leaving the study n	Predominant trauma type (%)	Mean duration of trauma symptoms	Age, year Mean (range)	Outcome measures	Risk of bias assessment						
										Adequate sequence generation	Allocation concealment	Blinding of participants, personnel and outcome assessors	Incomplete outcome addressed	Free from selective reporting	Free from other bias	
Baker (1995) <sup>30</sup> USA	Multicentre, randomised, double-blind, parallel, placebo-controlled, flexible dose brofaromine up to 150 mg	12 weeks	DSM-III-RCAPS >45MADS <22 >6 months	146 (19)	35	Combat (60)	12.8 years	44 (23–73)	CAPSIES	Unclear	Unclear	Unclear	High	High	Unclear	
Brady (2000) <sup>31</sup> USA	Multicentre, randomised, double-blind, parallel, placebo-controlled, flexible dose sertraline 50–200 mg (193.3 mg)	12 weeks	DSM-III-RCAPS >50 >6 months	187 (73)	50	Sexual assault (61)	12 years	40 (18+)	CAPSIDTSCGIC-SCGI-IHRSD	Unclear	Unclear	Unclear	Unclear	Low	High	
Brady (2005) <sup>32</sup> USA	Randomised, double-blind, parallel, placebo-controlled, fixed dose sertraline	12 weeks	DSM-IV/concurrent alcoholism	94 (46)		Physical assault (50)		36.7 (18–65)	CAPSHRS	Alcohol use severity	Low	Unclear	Unclear	High	Low	Unclear
Braun (1990) <sup>33</sup> Israel	Randomised, double-blind, cross-over, placebo-controlled, 2 week titrated placebo washout flexible dose alprazolam 1.5–6 mg (4.65 mg)	5 weeks	DSM-III	13 (0)	6	Combat (40)	4.3 years	37.7	DSM-based PTSD scale/ESRHS/DSRASAVS	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	
Butterfield (2001) <sup>34</sup> USA	Randomised, double-blind, parallel, placebo-controlled, flexible dose clonazepam 5–20 mg (14.1 mg)	10 weeks	DSM-IV	15 (93)	4	Rape (53)		43.2 (18–70)	DTI-SESSPRINTOP-8	Unclear	Unclear	Unclear	Low	Low	High	
Carey (2012) <sup>35</sup> South Africa	Single centre, randomised, double-blind, parallel, placebo-controlled, flexible dose clonazepam 5–15 mg (9.2 mg)	8 weeks	DSM-IVCAPS >50 >3 months	34 (60% female of n = 28)	10	Domestic violence and criminal violence		40.5 (range 18+ of n = 28)	CAPSIDTSCGIDSDS	Unclear	Low	Unclear	Unclear	Low	High	
Connor (1999) <sup>36</sup> USA	Randomised, double-blind, parallel, placebo-controlled, flexible dose fluoxetine 10–60 mg (30 mg)	12 weeks	DSM-IV-R	54 (91)	17	Rape (26)	6 years	32 (18–55)	DGRSPIDTSDSOS	Low	Low	Unclear	Unclear	Low	Unclear	
Connor (2005) <sup>37</sup> USA	Responders to open label treatment randomised to double-blind, placebo-controlled discontinuation phase, flexible dose tigabine 4–12 mg (10.8 mg)	12 weeks	DSM-IVCGI-S >4	18 (0)	5			18–65	SPRINTSIPCGI-SDTSHRSDDC-RSCPSQISDI	Unclear	Unclear	Unclear	Unclear	Low	High	
Davidson <sup>38</sup> USA	Multicentre, randomised, double-blind, placebo-controlled, parallel fixed dose venlafaxine 37.5–300 mg (164.4 mg) v. sertraline 25–200 mg (110.2 mg)	12 weeks	DSM-IVCAPS >60DTS >40 >6 months	538 (65)	218	Non-sexual abuse (26)		32 (18+)	CAPSCGI-SDTSGAF	Unclear	Unclear	Unclear	High	Low	High	
Davidson (1990) <sup>39</sup> USA	Randomised, double-blind, parallel, placebo-controlled, flexible dose amitriptyline 50–300 mg (116 mg)	8 weeks	DSM-III	46 (0)	13	Combat (100)			CGI-BSI-PTSDCGI-SHRSRHSRAESNIEPI	Unclear	Unclear	Unclear	Low	Low	Unclear	
Davidson (2001) <sup>40</sup> USA	Multicentre, randomised, double-blind, parallel, placebo-controlled, flexible dose sertraline 20–200 mg (137 mg), relapse prevention follow-on label study	28 weeks	DSM-III-RCAPS-2 > 50 >6 months	96 (30)	48	Physical or sexual assault (52)	13.05 years	43 (21–69)	CGI-SCGI-IIESCAPS	Unclear	Unclear	Unclear	Unclear	Low	High	
Davidson (2001) <sup>41</sup> USA	Multicentre, randomised, double-blind, parallel, placebo-controlled, flexible dose sertraline 50–200 mg (146.3 mg)	12 weeks	DSM-III-RCAPS-2 >50 >6 months	208 (22)	77	Physical/sexual assault (62)	12.2 years	37.1 (18–69)	CGI-ICGI-IIESCAPS	Low	Unclear	Unclear	Unclear	Low	High	
Davidson (2003) <sup>42</sup> USA	Randomised, double-blind, parallel, placebo-controlled, fixed dose mirazepine 15–45 mg (38.8 mg)	8 weeks	DSM-IVSP	29 (0)	6	Mixed		46.5	SPRINTCGI	Unclear	Unclear	Unclear	Unclear	Low	High	
Davidson (2004) <sup>43</sup> USA	Remission data pooling from two double-blind placebo-controlled 12-week flexible dose sertraline comparison trials	12 weeks	DSM-IVCAPS >50 >6 months	384 (75)	127	Physical/sexual assault	12.1 years	38 (18–69)	CGI-SCGI-IDTIESCAPS-2	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	
Davidson (2005) <sup>44</sup> USA	Six months open label treatment followed by 6 months randomised, double-blind, placebo-controlled, flexible dose fluoxetine 10–60 mg (48.6 mg) (discontinuation phase)	6 months	Mini criteria	62 (50)	32	Combat (32)		44.1 (18–70)	SPRINTCGI-SDTS	Unclear	Unclear	Unclear	Unclear	High	Unclear	
Davidson (2006) <sup>45</sup> International	Multicentre, randomised, double blind, parallel, placebo-controlled, flexible dose venlafaxine 37.5–300 mg (181.7 mg)	24 weeks	DSM-IVCAPS >60 >6 months	329 (54)	105	Assault (57)		41.35 (18+)	CAPS-SX17CGI-SGAFHRS-17CD-RISC-SVQLES-SDS	Low	Unclear	Low	Low	Low	High	
Davidson (2007) <sup>46</sup> USA	Multicentre, randomised, double blind, parallel, placebo-controlled, flexible dose sertraline 50–200 mg (135 mg)	12 weeks	DSM-IVCAPS >50 >50 >50 >50	232 (56)	91	Physical/sexual assault (53)	13.1 years	42.6 (16–64)	CAPSIDTSTOP-8CGI-CCDR-SSDSM3QAMADS	Unclear	Unclear	High	High	Unclear	Unclear	
Davis (2001) <sup>47</sup> USA	Randomised, double-blind, parallel, placebo-controlled, flexible dose nefazodone 200–600 mg (435 mg)	12 weeks	DSM-IV	42 (2)	19	Combat (98)	29.9 years	53.8 (32–75)	CAPSIRSAHRSOPTSD checklist/CDSSGAFSCGI	Unclear	Low	Low	Low	High	High	
Davis (2006) <sup>48</sup> USA	Randomised, double-blind, parallel, placebo-controlled, flexible dose divalproex 500–300 mg (230 mg)	8 weeks	DSM-IVCAPS >45	85 (2)	17	Combat (95)	24.4 years	55.2 (19–70)	CAPSTOP-8MADRS/CGI-SGCI-IHRS	Low	Low	Unclear	Low	Low	Low	
Eli Lilly <sup>49</sup>	Randomised, double-blind, placebo-controlled, parallel arm, fixed dose fluoxetine 20–40 mg v. 40 mg	12 weeks		411 (0)	259				CGI-STOP-8	Unclear	Unclear	Unclear	High	High	High	
Friedman (2007) <sup>50</sup> USA	Multicentre, randomised, double-blind, parallel, placebo-controlled, flexible dose sertraline 50–200 mg (135 mg)	12 weeks	DSM-III-RCAPS >5 >6 months	169 (21)	40	Combat (71)	18 years	45.5 (18+)	CAPSCGI-ICGI-SDTSHRSARSDPSQIDESMISS	Low	Unclear	Low	Unclear	Low	Unclear	
Huahai <sup>51</sup> China	Preventative, randomised, double-blind, placebo-controlled, flexible dose paroxetine 10–20 mg	1 month	DSM-V Healthy population	53 (41)	0	Natural disaster (100)		36.4 (18+)	PCPLPTSD self-rating scale	Unclear	Unclear	Unclear	Low	High	Unclear	
Hertzberg (1999) <sup>52</sup> USA	Randomised, double-blind, parallel, placebo-controlled, flexible dose lamotrigine 25–50 mg (380 mg)	12 weeks	DSM-IVSP	15 (36)	6	Combat (71)		43.4 (29–53)	SIPDGPB	Unclear	Unclear	Unclear	Low	High	High	
Hertzberg (2000) <sup>53</sup> USA	Randomised, double-blind, parallel, placebo-controlled, flexible dose fluoxetine 10–40 mg (48 mg)	12 weeks	DSM-IIIR	12 (0)	1	Combat (100)		46 (44–48)	DGRPDOTSSDSSIP	Unclear	Unclear	Unclear	Unclear	High	Unclear	
Katz (1994) <sup>54</sup> USA	Multicentre, randomised, double-blind, parallel, placebo-controlled, flexible dose brofaromine 50–150 mg	14 weeks	DSM-III-RCAPS >36	68 (24)	23	Physical assault (38)	2.8 years	39 (22–62)	CAPSCGI	Unclear	Unclear	Unclear	High	High	High	
Kosten (1991) <sup>55</sup> USA	Multicentre, randomised, double-blind, parallel, placebo-controlled, flexible dose imipramine 50–300 mg (225 mg) v. phenelzine 15–75 mg (68 mg)	8 weeks	DSM-III	60 (0)	28	Combat (100)		39	IESHRSARSDRSDCAS	Unclear	Unclear	Unclear	Unclear	Low	Low	
Marshall (2001) <sup>56</sup> USA	Multicentre, randomised, double-blind, parallel, placebo-controlled, fixed dose paroxetine 25 mg v. 50 mg	12 weeks	DSM-IV	563 (57)	208	Physical/sexual assault (48–54)	15.7 years	41.8 (18+)	CAPS-2CGI-IDSTOP-8SDSMADS	Unclear	Unclear	Unclear	High	Low	High	
Marshall (2004) <sup>57</sup> USA	Randomised, double-blind, parallel, placebo-controlled, flexible dose paroxetine 10–60 mg. Maintenance phase not included	10 weeks	DSM-IV>3 months	63 (0)	33	Physical assault or abuse (48)		39.8 (18–65)	CAPSCGI-PODES/IESHRSARSD	Unclear	Unclear	High	Low	High	Low	
Marsteller (2002) <sup>58</sup> International	Acute phase, multicentre, randomised, double-blind, parallel, placebo-controlled, flexible dose fluoxetine 20–80 mg (57.8 mg)	12 weeks	DSM-IVCAPS-DX >50CGI-S >4	301 (19)	139	Combat (47)		37.9 (18–65)	TOP-8CGI-SCGI-SGCI-IDTSMADRS/HSRAS-90-RDES	Low	Low	Unclear	Low	High	High	
Marsteller (2003) <sup>59</sup> International	Continuation phase, multicentre, randomised, double-blind, parallel, placebo-controlled, flexible dose fluoxetine 20–80 mg (57.8 mg)	24 weeks	DSM-IVCAPS-DX >50CGI-S >4	131 (19)	33	Non-combat (53)	5.15 years	38.3 (18–65)	TOP-8CGI-SCGI-SGCI-IDTSMADRS/HSRAS-90-RDES	Low	Low	Unclear	Low	Low	High	
Marsteller (2007) <sup>60</sup> USA	Multicentre, randomised, double-blind, parallel, placebo-controlled, fixed dose fluoxetine 20–40 mg (26.2 mg)	12 weeks	DSM-IV	20 (100)	8	Combat (100)		41.3 (19–65)	CAPSTOP-8HRSRHSRA	Unclear	Unclear	Unclear	High	High	Unclear	
Panahi (2011) <sup>61</sup> Iran	Randomised, double-blind, parallel, placebo-controlled, flexible dose sertraline 50–200 mg (140 mg)	10 weeks	DSM-IV-TRCGI-S >4 >6 months	70 (0)	8	Combat (100)	24.1 years	45.6	IES-RCGI-S	Low	Unclear	Low	Low	Low	Unclear	
Petrakis (2012) <sup>62</sup> USA	Multicentre, randomised, double-blind, parallel, placebo-controlled, flexible dose paroxetine 10–40 mg (39.7 mg) v. desipramine 25–200 mg (187.2 mg) (naltrexone groups not considered)	DSM-IV<29/ absent: 7 = 88 (9 n = 44 in monotherapy groups)		7 (monotherapy)	Combat (92)			47.1	CAPSHRS	Unclear	Unclear	Unclear	Low	Low	Unclear	
Pfizer S88 <sup>63</sup>	Multicentre, randomised placebo-controlled, double-blind, parallel	74 days	DSM-III-RCAPS-2 >50	193 (75)	50	Physical/sexual assault	10.5 years	37	CAPS-2CGI-IDSTOPSCGI-S	Unclear	Unclear	Unclear	High	High	High	
Pfizer S89 <sup>64</sup>	Randomised, double-blind, placebo-controlled, parallel flexible dose sertraline (156 mg)	72 days	DSM-IV-R	169 (20)	40	Combat (71)	18 years	45	CGI-SCGI-IDSTOPSCAPS-2	Unclear	Unclear	Unclear	High	High	High	
Reiss (1989) <sup>65</sup> USA	Multicentre, randomised, double-blind, cross-over, placebo-controlled, flexible dose desipramine 50–200 mg (165 mg)	8 weeks	DSM-III-R	27 (0)	9	Combat (100)		38.4 (28–64)	IESHRSARSDABI	Unclear	Unclear	Unclear	High	Low	Unclear	
Saygin (2002) <sup>66</sup> Turkey	Randomised, double-blind, parallel arm, flexible dose nefazodone 200–400 mg (332.4 mg) v. sertraline 50–200 mg (68.3 mg)	24 weeks	DSM-IV	60 (0)	6	Earthquake survivors		41.5	TOP-8CGI-ICGI-SCGI-SE	Unclear	Unclear	Unclear	High	Low	Unclear	
Shalev (2011) <sup>67</sup> Israel	Randomised, double-blind, parallel, placebo-controlled, fixed dose escitalopram 10–20 mg	20 weeks	DSM-IVCAPS >40, no minimum duration	46 (44)	7	RTA (83)	144.1 days	38.6 (18–70)	CAPS-SPS-SR	Low	Unclear	Low	Unclear	Low	Unclear	
SKB627E	Randomised, double-blind, parallel, placebo-controlled, flexible dose paroxetine 20–50 mg	84 days	DSM-IV	322 (53)				18–75	CAPS-2CGI-I	Unclear	Unclear	Unclear	High	High	High	
SKB50F	Randomised, double-blind, placebo-controlled, flexible dose paroxetine up to 50 mg	252 days	DSM-IVCAPS >50	176 (66)	46			43 (18–82)	CAPS-2DTSMDRSSDSD	Unclear	Unclear	Unclear	High	High	High	
Spijk (2006) <sup>68</sup> Israel	Randomised, double-blind, parallel, head-to-head comparator, fixed dose reboxetine 8 mg v. fluvoxamine 150 mg	8 weeks	DSM-IVCAPS >60 >1 month	40 (47)	12	RTA (100)		40.1	CAPSTOP-8HRSRHSRA	Low	Unclear	Low	High	Low	High	
Tucker (2001) <sup>69</sup> USA	Multicentre, randomised, double-blind, parallel arm, placebo-controlled, flexible dose paroxetine 20–50 mg (27.6 mg)	12 weeks	DSM-IV	323 (66)	152		14.9 years	40.8 (18–78)	CAPS-2CGI-IDSTOP-8SDSMADS	Unclear	Unclear	Unclear	High	Low	High	
Tucker (2003) <sup>70</sup> USA	Randomised, double-blind, parallel, placebo-controlled, flexible dose citalopram 20–50 mg (36.2 mg) v. sertraline 50–200 mg (134.1 mg)	10 weeks	DSM-IVCAPS >50	59 (72)	14	Physical abuse/assault (31)		38.5 (18–64)	CAPSIESBDI	Unclear	Unclear	Unclear	High	Low	High	
Tucker (2007) <sup>71</sup> USA	Randomised, double-blind, parallel, placebo-controlled, flexible dose topiramate 25–400 mg (150 mg)	8 weeks	DSM-IVCAPS >50No minimum duration	40 (80)	6	Childhood sexual abuse (34)		41.5 (18–65)	CAPSRSARSDTOP-8CGI-SCGI-IDTSSBSCD-RSC	Low	Unclear	Unclear	Low	Low	Unclear	
Van der Kolk (1994) <sup>72</sup> USA	Multicentre, randomised, double-blind, parallel arm, placebo-controlled, flexible dose fluoxetine 20–60 mg (40 mg)	5 weeks	DSM-IV-R	64 (34)	17	Combat (44)		40.4 (22–55)	CAPSDOHIIHRSDESDI	Unclear	Unclear	Unclear	High	Low	Unclear	
Van der Kolk (2004) <sup>73</sup> USA	Multicentre, randomised, double-blind, parallel arm, placebo-controlled, flexible dose paroxetine 20–50 mg (27.6 mg)	5 weeks	DSM-IV>12 months	59 (86)	7	Interpersonal victimisation	13.1 years	34.9 (18–65)	CAPSDBI	Unclear	Unclear	Unclear	Low	Low	Low	
Yeh (2010) <sup>74</sup> Brazil	Randomised, double-blind, parallel, placebo-controlled topiramate 50–200 mg (102.9 mg) v. EMDR	12 weeks	DSM-IV	35 (68)	21	Violence (100)		40.1 (18–62)	CAPSDICGI	Low	Unclear	Unclear	Low	Low	Unclear	
Zohar (2002) <sup>75</sup> Israel	Multicentre, randomised, double-blind, parallel arm, placebo-controlled, flexible dose sertraline 50–200 mg (120 mg)	10 weeks	DSM-III-RCAPS-2 >50 CGD-S >4 >6 months	51 (37/42)	20	Combat (32/42)		40 (18+)	CAPS-2CGI-ICGI-SMARDSLOC	Unclear	Unclear	Unclear	High	Low	High	

BDI, Beck Depression Inventory; CADS, Clinician Administered Dissociative States Scale; CAPS, Clinician Administered PTSD Scale; CAPS-2, CAPS part 2; CAPS-DX, CAPS Diagnosis; CAPS-XIT, CAPS Item 17-item; CAS, Cov Anxiety Scale; CD-RS, Children's Depression Rating Scale Revised; DTS, DSM Trauma Scale; EMDR, Eye Movement Desensitisation and Reprocessing; EPI, Eysenck Personality Inventory; GAF, Global Assessment of Functioning; HRS, Hamilton Rating Scale for Anxiety; IES, Impact of Events Scale; IPP, Inventory of Personal Problems; LCF, last observation carried forward; MADRS, Montgomery–Asberg Depression Rating Scale; M-Health, Mobile Health; PDS, Post-Traumatic Stress Symptoms Scale; PSS-Rev, Post-Traumatic Stress Symptom Scale; PSS-SR, PSS Self-rated; QLES-Q, Quality of Life and Satisfaction Short Form; RTA, Road traffic accident; SC-90-R, Hopkins 90-item Treatment Outcome PTSD Scale; VAS, Visual Analog Scale; VS, Vulnerability to the Effects of Stress Scale.

BDI, Beck Depression Inventory; CADS, Clinician Administered Dissociative States Scale; CAPS, Clinician Administered PTSD Scale; CAPS-2, CAPS part 2; CAPS-DX, CAPS Diagnosis; CAPS-XIT, CAPS Item 17-item; CAS, Cov Anxiety Scale; CD-RS, Children's Depression Rating Scale Revised; DTS, DSM Trauma Scale; EMDR, Eye Movement Desensitisation and Reprocessing; EPI, Eysenck Personality Inventory; GAF, Global Assessment of Functioning; HRS, Hamilton Rating Scale for Anxiety; IES, Impact of Events Scale; IPP, Inventory of Personal Problems; LCF, last observation carried forward; MADRS, Montgomery–Asberg Depression Rating Scale; M-Health, Mobile Health; PDS, Post-Traumatic Stress Symptoms Scale; PSS-Rev, Post-Traumatic Stress Symptom Scale; PSS-SR, PSS Self-rated; QLES-Q, Quality of Life and Satisfaction Short Form; RTA, Road traffic accident; SC-90-R, Hopkins 90-item Treatment Outcome PTSD Scale; VAS, Visual Analog Scale; VS, Vulnerability to the Effects of Stress Scale.

BDI, Beck Depression Inventory; CADS, Clinician Administered Dissociative States Scale; CAPS, Clinician Administered PTSD Scale; CAPS-2, CAPS part 2; CAPS-DX, CAPS Diagnosis; CAPS-XIT, CAPS Item 17-item; CAS, Cov Anxiety Scale; CD-RS, Children's Depression Rating Scale Revised; DTS, DSM Trauma Scale; EMDR, Eye Movement Desensitisation and Reprocessing; EPI, Eysenck Personality Inventory; GAF, Global Assessment of Functioning; HRS, Hamilton Rating Scale for Anxiety; IES, Impact of Events Scale; IPP, Inventory of Personal Problems; LCF, last observation carried forward; MADRS, Montgomery–Asberg Depression Rating Scale; M-Health, Mobile Health; PDS, Post-Traumatic Stress Symptoms Scale; PSS-Rev, Post-Traumatic Stress Symptom Scale; PSS-SR, PSS Self-rated; QLES-Q, Quality of Life and Satisfaction Short Form; RTA, Road traffic accident; SC-90-R, Hopkins 90-item Treatment Outcome PTSD Scale; VAS, Visual Analog Scale; VS, Vulnerability to the Effects of Stress Scale.

## Appendix DS1 Electronic search strategy

1. Stress Disorders, Traumatic/ or Combat Disorders/ or Stress Disorders, Post-Traumatic, Acute/ or Stress Disorders, Post-Traumatic/ or Stress, Psychological/
2. Stress, Psychological/ or Critical Incident Stress/ or Stress Disorders, Post-Traumatic/
3. Posttraumatic Stress Disorder/ or Emotional Trauma/ or Traumatic Neurosis/
4. Posttraumatic Stress Disorder/ or Psychotrauma/
5. (post?traumatic\$ or post-traumatic\$ or stress disorder\$ or acute stress or PTSD or ASD or DESNOS).tw.
6. (combat neuros\$ or combat syndrome or concentration camp syndrome or extreme stress or flash?back\$ or flash-back\$ or hypervigilan\$ or hypervigilien\$ or psych\$ stress or psych\$ trauma\$ or psycho?trauma\$ or psycho-trauma\$).tw.
7. (railway spine or (rape adj2 trauma\$) or re?experienc\$ or re-experienc\$ or torture syndrome or traumatic neuros\$ or traumatic stress).tw.
8. (trauma\$ and (avoidance or grief or horror or death\$ or night?mare\$ or night-mare\$ or emotion\$)).tw.
9. grief bereav\*.tw
10. or/1-9
11. exp clinical trials/ or cross-over studies/ or random allocation/ or double-blind method/ or single-blind method/
12. random\$.pt.
13. exp clinical trial/ or crossover procedure/ or double blind procedure/ or single blind procedure/ or randomization/
14. exp clinical trials/ or crossover design/ or random assignment/
15. exp clinical trials/ or double blind method/ or random allocation/
16. random\$.mp.
17. (cross-over or cross?over or (clinical adj2 trial\$) or single-blind\$ or single?blind\$ or doubleblind or double?blind\$ or triple-blind or triple?-blind).tw.
18. randomized controlled trial/
19. matched pair analysis/
20. cohort study.tw
21. case-control.tw
22. before-and-after studies.tw
23. epidemiological studies.tw
24. intervention studies.tw
25. or/11-24
26. mask\*.tw
27. blind\*.tw
- 28.-latin square\$.tw
29. placebos/
30. placebo\*.tw
31. random\*.tw
32. research design/
33. comparative study/
34. evaluation studies/
35. follow-up studies/
36. prospective studies/
37. control\*.tw
38. prospectiv\*.tw
39. volunteer\*.tw
40. or/26-39
41. animals/ not (animals/ and human\$.mp.)
42. animal\$/ not (animal\$/ and human\$/)
43. meta-analysis/
44. meta-analysis.pt.
45. systematic review/
46. or/41-45
47. 25 not 46
48. pharmacother\*.tw
49. pharmacolog\*.tw
50. antipsychotic\*.tw
51. Psychopharmacology/
52. Benzodiazepines/
53. antidepressive agents/
54. hypnotics/
55. sedatives/
56. medicat\*.tw
57. drug\*.tw
58. drug therapy/
- 59.-Antidepressive Agents€
- 60.-Monoamine Oxidase Inhibit ORs€
- 61.-Selective Serotonin Reuptake InhibitORs€
- 62.-Tricyclic Drugs€
63. Acetyl carnitine
64. Alaproctate
65. Amersergide
66. Amiflamine
67. Amineptine
68. Amitriptyline
69. Amoxapine
70. Befloxtatone
71. Benactyzine
72. Beta blockers
73. Beta\*.tw
74. Brofaromine
75. Bupropion
76. Butriptyline
77. Caroxazone
78. ChlORpoxiten
79. Cilosamine
80. Cimoxatone
81. Citalopram
82. Clomipramine
83. ClORgyline
84. ClORimipramine
85. Clovoxamine
86. Cortisol
87. Deanol
88. Demexiptiline

89. Deprenyl  
90. Desipramine  
91. Dibenzipin  
92. Diclofensine  
93. Dothiepin  
94. Doxepin  
95. Duloxetine  
96. Escitalopram  
97. Etoperidone  
98. Femoxetine  
99. Fluotracen  
100. Fluoxetine  
101. Fluparoxan  
102. Fluvoxamine  
103. Hydrocortisone  
104. Idazoxan  
105. Imipramine  
106. Iprindole  
107. Iproniazid  
108. isocarboxazid  
109. Litoxetine  
110. Lofepramine  
111. Maprotiline  
112. Medifoxamine  
113. Melitracen  
114. Metapramine  
115. Mianserin  
116. Milnacipran  
117. Minaprine  
118. Mirtazapine  
119. Moclobemide  
120. Nefazodone  
121. Nialamide  
122. Nomifensine  
123. NORtriptyline  
124. Noxiptiline  
125. Opipramol  
126. Oxflozane  
127. Oxaprotiline  
128. Pargyline  
129. Paroxetine  
130. Phenelzine  
131. Pirbedil  
132. Pirlindole  
133. Pivagabine  
134. Propranol  
135. Prosulpride  
136. Protriptyline  
137. Quinupramine  
138. Reboxetine  
139. Rolipram  
140. Sertraline  
141. Setiptiline  
142. Teniloxine  
143. Tetrindole  
144. Thiazesim  
145. Thozalinone  
146. Tianeptine  
147. Toloxatone  
148. Tomoxetine  
149. Tranylcypromine  
150. Trazodone  
151. Trimipramine  
152. Venlafaxine  
153. Viloxazine  
154. Viqualine  
155. Zimeldine  
156. beta blockers  
157. beta\*.tw.  
158. cortisol  
159. hydrocortisone  
160. or/48-159  
161. 10 and 25 and 40 and 46 and 47 and 159